Saturday, August 29, 2026
BioNTech, Genentech halt mRNA colorectal cancer vaccine trial
BioNTech and Roche's Genentech terminated a Phase 2 trial of their individualized mRNA cancer vaccine autogene cevumeran (BNT122) in adjuvant colorectal cancer on August 28, after an independent data safety monitoring board recommended discontinuing treatment. The trial had tripped a futility threshold back in October 2025 but was kept running for more data; BioNTech's US-listed shares fell nearly 9% on the news, while the companion Phase 2 trial of the same vaccine in adjuvant pancreatic cancer continues.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- Health Canada authorizes BioNTech XFG Comirnaty shotSunday, September 20, 2026
- BioNTech combo posts 70 percent ORR in SCLCTuesday, September 15, 2026
- Gotistobart nearly doubles survival in squamous NSCLCMonday, September 14, 2026
- BioNTech halts Phase 2 colorectal cancer vaccine trialFriday, September 4, 2026